Aromatase inhibitors (AIs) are first-line post-menopausal agents for oestrogen receptor alpha (ERα)-positive breast cancer. However, there is considerable response heterogeneity and women frequently relapse. Oestrogen (E)-deprivation does not completely arrest ERα-activity and transactivation of the unliganded receptor may continue through cross-talk with growth factor pathways. In contrast to AIs, the selective ER down-regulator fulvestrant also abrogates ligand-independent ERα-activity. The benefit of fulvestrant as an alternative, combination or sequential therapy to AIs has been reported, but molecular mechanisms underpinning its relative efficacy remain unclear and biomarkers for patient selection are lacking. This 
INTRODUCTION
Endocrine therapies abrogate oestrogenic signalling through distinct mechanisms, impeding oestrogen (E) synthesis or transcriptional activity of oestrogen receptor alpha (ERα). Aromatase inhibitors (AIs), e.g. anastrozole, cause profound postmenopausal E-suppression and are used as first-line neo-adjuvant, adjuvant and metastatic therapies. Selective oestrogen receptor modulators (SERMs), e.g. tamoxifen, exert partial agonist activity. In contrast, the selective ER down-regulator (SERD) fulvestrant (Faslodex ® , AstraZeneca) is a pure anti-oestrogen, inhibiting receptor dimerisation, nuclear uptake, E-response element binding and accelerating ERα degradation (1) (2) (3) (4) (5) .
Fulvestrant is licensed for post-menopausal progression/relapse on first-line endocrine therapy (6) (7) (8) . Low-dose fulvestrant (250mg/28 days) provides comparable disease outcome to anastrozole following first-line tamoxifen in metastatic disease (6) (7) (8) , with utility after progression on AIs (9-11). As first-line therapy in metastatic or locally advanced disease, low-dose fulvestrant provides comparable disease outcome to tamoxifen (12) . High-dose treatment (500mg on day 0, 14, 28, monthly thereafter) further improved progression-free (13) and overall survival (14) in the COmparisoN of Faslodex In Recurrent or Metastatic breast cancer (CONFIRM) trial.
The Fulvestrant fIRst-line Study comparing endocrine Treatments (FIRST), found an improved time to progression with the high-dose compared to anastrozole (1mg/day) in advanced disease (15, 16) . In the Neo-adjuvant Endocrine therapy for Women with Estrogen-Sensitive Tumours (NEWEST) trial of locally advanced disease, highdose fulvestrant showed greater suppression of ERα, progesterone receptor (PgR), the proliferation marker Ki67 and radiological response than low-dose (17) . These Author Manuscript Published OnlineFirst on June 10, 2014; DOI: 10.1158/1078-0432.CCR- data show significant differences between fulvestrant dosing schedules and a mechanism of action which is different to, and may circumvent complete crossresistance with, SERMs and AIs. The molecular mechanisms which underpin these clinically important differences are incompletely understood.
The transcriptional response to fulvestrant differs from SERMs, with the latter up-regulating particular E-regulated genes (ERGs) (18) . In addition to more complete ERG antagonism, fulvestrant exclusively down-regulates numerous cell cycle, proliferation, and DNA synthesis genes in vitro (19) , and some E-suppressed genes are up-regulated by fulvestrant and not tamoxifen (20) . The transcriptional response to AIs and fulvestrant has not previously been compared and may be pertinent to the clinical utility of fulvestrant as an alternative, sequential or combination therapy. The potential for difference is supported by their contrasting effects on E and ERα. The interaction between E and ERα underpins classical oestrogenic signalling which is susceptible to both AIs and fulvestrant. Contemporary models also include activities which do not require interaction and may involve either E or ERα independently (21) (22) (23) (24) (25) (Figure 1a ). Such non-classical activities might be affected selectively by AIs and fulvestrant respectively (Figure 1b) . In vitro, the greater anti-proliferative effect of fulvestrant (26) , has been attributed to continued ERα activity following E-withdrawal, with hypersensitivity to residual E and/or E-independent interactions between ERα and growth factor pathways. ERα has recently been shown to retain genomic binding activity following E-withdrawal and drive a CDK4/E2F-dependent transcriptional program. Such ligand-independent ERα activity has particular relevance to de novo and acquired AI resistance, where ERα is frequently expressed and fulvestrant may remain effective (9, 10, 27 
Author Manuscript Published OnlineFirst on June 10, 2014; DOI: 10.1158/1078-0432.CCR- In this study, global gene expression profiles from pre-surgical studies of fulvestrant or anastrozole, and corresponding in vitro models, were assessed. The primary objective was to compare and contrast transcriptional responses. Secondary objectives included evaluating the biological response to low-and high-dose fulvestrant and the extent to which transcriptional consequences were attributable to ERα depletion.
MATERIALS & METHODS

Pre-surgical study of fulvestrant
Pre-and on-treatment (four-week) core biopsies stored at -20ºC in RNA-later (Qiagen, Sussex, UK) were available from NEWEST (ClinicalTrials.gov-NCT00093002) (17) , Supplementary Figure S1 . This phase-II study recruited postmenopausal women with untreated, potentially operable, locally advanced, ERα-positive, primary invasive cancer ≥2 cm. No data were available for HER2 status.
Randomisation was to low-(250mg/28 days) or high-dose (500mg on day 0, 14, 28, monthly thereafter) fulvestrant. The on-treatment biopsy was taken prior to the day 28 dose of fulvestrant in both arms of the study. RNA was extracted with RNeasy, assessed using an Agilent Bioanalyser (Santa Clara, CA, USA) and rejected if RNA integrity number <5. Following exclusions, 22 high-dose and 16 low-dose pre-/ontreatment pairs were available, Supplementary Figure S1 .
Research. Pre-surgical study of anastrozole Pre-and on-treatment (two-and sixteen-week) core biopsies were available from post-menopausal women receiving anastrozole monotherapy (1mg/day) within a randomised phase-II neo-adjuvant trial of anastrozole alone or with gefitinib in early disease (ClinicalTrials.gov-NCT00255463) (28) . This subgroup constitutes the 
Global gene expression analysis
Raw expression data were extracted with BeadStudio, transformed by variancestabilising transformation (VST) and normalised using Robust Spline Normalisation (RSN) in the Lumi package in Bioconductor. Probes were excluded if they were not present in any samples (detection p-value>1%). Microarray data are publicly available (29) (30) (31) (32) of all possible patients). Transcripts differentially expressed between fulvestranttreated, E-deprived and control conditions in vitro were identified by ANOVA. A false discovery rate (FDR) of 5% was used to correct for multiple testing.
Analytical strategy
Matched Illumina probe identifiers were used to enable valid comparisons between (Hs0950344_m1), which were normalised to FKBP15 (Hs0391480_m1) and PUM1 (Hs0982775_m1).
ESR1 knockdown in MCF7 cells
MCF7 cells were seeded into DCC at a density of 7x10 4 cells/well in 12 well plates.
After 24 hours monolayers were transfected with 50nM of siRNA targeting ESR1
(ON-TARGETplus 003401, Dharmacon, ThermoFisher, UK), or non-targeting siRNA using DharmaFECT 3 reagent. Media (0.1nM E2 in DCC) was replenished the following day and cells were cultured for 24 hours. TaqMan assays were used to quantify ESR1 (Hs01046818_m1), and selected genes:
and STRA13 (Hs0414534_m1), which were normalised to FKBP15.
RESULTS
Transcriptional response to high-and low-dose fulvestrant
The overall transcriptional response to low-dose fulvestrant was significantly correlated with that to high-dose (Pearson r=0.36, p<0.0001), albeit of lesser Table S1 .
In contrast, 2210 transcripts were significantly affected (977 up-regulated and 1233 down-regulated, FDR<0.05) in the high-dose cohort. Further comparative analyses were undertaken with only high-dose treated patients to avoid the potential for falsenegativity by inclusion of those receiving low-dose fulvestrant.
Similarities in the transcriptional response to fulvestrant and E-deprivation
The overall transcriptional response to anastrozole and high-dose fulvestrant in pre- Proliferation-associated genes were also down-regulated by E-deprivation (e.g. GO sets, pathways and networks were prominent in transcripts affected by both treatments (Supplementary Tables S5-8 ). Ki67 staining was comparably reduced in samples from patients receiving anastrozole (geometric mean of post-/pre-treatment expression=24.8% after two weeks, n=69) and fulvestrant (19.6%, following highdose treatment, n=22).
Differences in the transcriptional response to fulvestrant and E-deprivation
The overall transcriptional response to high-dose fulvestrant was of greater magnitude than anastrozole in pre-surgical studies (slope=0.62, Figure 2b To assess whether transcript differences might be sufficient to influence distinct biological processes, differentially affected GO sets were identified in the same manner (Figure 3b , detailed in Supplementary Table S2 ). Fulvestrant downregulated 32 GO sets significantly more than E-deprivation. Common downregulated sets were predominantly proliferation-related (e.g. DNA helicase activity, microtubule motor activity and spindle assembly, Supplementary 
by E-deprivation (e.g. apoptotic signalling pathway, and negative regulation of: ERK1/2 cascades, TGFβ receptor signalling, canonical Wnt receptor signalling and epithelial cell proliferation, p<0.001 for the comparison of those not similarly upregulated). Some GO sets specifically up-regulated by fulvestrant pertained to fulvestrant-specific up-regulated genes (e.g. caveolae assembly and CAV1/CAV2).
Fulvestrant up-regulated 12 GO sets significantly more than E-deprivation (e.g. negative regulation of MAPK cascade). Treatment-related and -specific alterations in GO sets are summarised in Figure 3c (ii) and detailed in Supplementary Table S10 .
Pathway and network analysis of fulvestrant-specific genes
Canonical pathways associated with fulvestrant-specific genes (n=28, 11 upregulated and 17 down-regulated) included signalling through heterotrimeric Gproteins (β-/γ-subunits) and E-mediated S-phase entry (Table 1) To determine if this functional alliance of fulvestrant-specific genes was specifically induced by, and attributable to, congruent response to fulvestrant, their pre-treatment expression was assessed. Fulvestrant-related genes correlated significantly with one another at baseline; up-regulated genes were co-expressed, as were down-regulated genes, and these two groups were already inversely correlated, implicating a pre-existing regulatory system. Fulvestrant down-regulated genes correlated directly, whereas those up-regulated correlated inversely, with baseline AURKA and ESR1 (summarised in Supplementary Figure S2 and detailed in Supplementary Table S11).
Treatment-related gene alterations and anti-proliferative response
To determine if baseline expression of treatment-related genes (n=46) was associated with anti-proliferative response, their pre-treatment levels were correlated with change in AURKA expression. Twenty-six genes correlated with response to anastrozole or high-dose fulvestrant (uncorrected p<0.05), summarised in Figure 5a and detailed in Supplementary Table S12. Twenty-three fulvestrant-related genes correlated with response to high-dose fulvestrant, with 5/23 (C9orf140, POLD2, SAC3D1, ZMYND19 and STRA13) also doing so in the low-dose treated cohort (Supplementary Table S12c ). Notably, 18/23 were not associated with response to anastrozole. Fulvestrant response was specifically associated with low pre-treatment expression of two genes (SNAI2 and NRP1) found to be up-regulated by fulvestrant, and high expression of 16 genes found to be down-regulated by fulvestrant; of these C9orf140, LRP8 and CCDC34 had predictive significance independent of pretreatment AURKA expression (p<0.05), Figure 5b Pre-treatment expression of five genes had predictive significance for both agents and their correlation was invariably stronger with response to fulvestrant.
Anastrozole response was specifically correlated with three genes, of which KCNK15 was E-deprivation-related and SKP2 had predictive significance independent of pretreatment AURKA expression, Figure 5b 
ESR1 knockdown in MCF7 cells
Knockdown of ESR1 invariably down-regulated the expression of genes which were found to be differentially down-regulated by fulvestrant (e.g. LRP8 and GTSE1) and up-regulated the expression of some genes which were differentially up-regulated by fulvestrant (e.g. SNAI2 and SEPP1), but not others (e.g. CAV1 and RBMS1). The majority of genes responded concordantly to fulvestrant and ESR1 knockdown (Supplementary Figure S3) .
DISCUSSION
This study compared, for the first time, transcriptional profiles from breast cancer in situ following fulvestrant or anastrozole and corresponding in vitro models. The robust integrative strategy avoids the identification of spurious genes in clinical samples which may reflect increasing proportions of stroma with treatment response (33) . The approach taken may discard alterations inadequately modelled in vitro, including those dependent upon three-dimensional structure, stromal interactions and hypoxia, but focuses on those genes which may be subjected to functional interrogation in model systems. The hallmark molecular responses to interrupted oestrogenic signalling, including suppression of ERGs and proliferative markers, followed both fulvestrant and E-deprivation. However, distinguishing features were apparent. Firstly, the overall transcriptional response to fulvestrant was of greater magnitude. Secondly, differences were not distributed uniformly across the transcriptome, but were most marked in a relatively limited cohort of genes. A small number of differentially affected genes were specific to E-deprivation, potentially attributable to ERα-independent E-activity (34) . Most were fulvestrantspecific and remained unaffected by extended anastrozole treatment, raising the possibility of regulation by unliganded ERα. Both fulvestrant and E-deprivation abrogate E-dependent ERα activity, but only fulvestrant, by virtue of ERα depletion, antagonises E-independent ERα activity, including cross-talk with growth factor pathways (26) . The greater and differential transcriptional response to fulvestrant may be attributable to the arrest of E-independent ERα activity that is unaffected by E-deprivation (27) . This greater anti-oestrogenic effect is consistent with the greater efficacy of fulvestrant in studies comparing the agents as first-line therapy in advanced disease (16) and in its sequential utility after AI relapse (9, 10).
Incompletely overlapping transcriptional responses are also consistent with the reported efficacy of combination therapy with fulvestrant and anastrozole (35) .
Fulvestrant-specific genes associated in networks with ERα, AR and TP53.
ERα activity can be influenced by cross-talk with AR signalling (36), which may exert anti-oestrogenic/anti-proliferative effects in ERα-positive breast cancer, while having contrasting roles in ERα-negative tumours (37) . The discovery of a subset of DNA binding elements and pioneer factors common to both receptors (38) SNAI2 encodes SLUG, a transcription factor implicated in breast cancer progression, nodal involvement and metastasis (44, 45) . Expression is associated with epithelialmesenchymal-transition, E-cadherin down-regulation and stem cell-associated gene expression (46, 47) . NRP1, encoding neuropilin-1, a co-receptor for semaphorins and vascular endothelial growth factor (VEGF), also has links with stem cell phenotype (48) concentrations on day 28 (50) , and the increased efficacy observed in the NEWEST (17) and CONFIRM trials (13, 14) .
Limitations of this study include in vitro modelling using a single cell line, which is also PIK3CA mutated, and expression profiling across different BeadChip versions which reduced the number of comparable probes. Potential confounding factors also include better patient compliance with treatment regimens in favour of fulvestrant given its mode of administration (although good E-suppression was found in the AI treated patients -data not shown) and duration of treatment; extended anastrozole treatment may have induced further changes in gene expression. Nonrandomised comparisons may also be influenced by selection-bias, with differences in baseline patient and tumour characteristics between pre-surgical studies with incompletely overlapping entry criteria, and differences such as details in sample taking, storage and ethnicity of the populations. Sample sizes may have also restricted the statistical power to identify treatment-induced changes.
In conclusion, the molecular response to fulvestrant has much in common with E-deprivation, but is stronger with distinctions potentially attributable to arrest of E-independent ERα activity and involvement of AR signalling. Genes responding differently to fulvestrant may have specific predictive utility. These data are consistent with the efficacy of first-line fulvestrant versus anastrozole in advanced disease, combination therapy in the metastatic setting, sequential utility after AI relapse, and higher dosing regimens. 
